Cellectis
  • About
    Our mission
    Governance
    Partners
  • Science
    Our Genome Engineering Platform
    TALEN® Technology
    In-House Manufacturing
  • Pipeline
    Product Candidates
  • Investors
    IR Overview
    News
    • Press releases
    • Events and Webcasts
    Presentations
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    Corporate Governance
    • Board of Directors
    • Executive Committee
    • External Auditors
    • Governance Documents
    • General meetings
    Financial Information
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    Shareholders Services
    • IR Inquiries
    • IR FAQ
  • Careers
    Our culture
    Job opportunities
  • Contact us
LinkedinX FR
› Investors › Voting Rights & Share Capital
  • About
    • Our mission
    • Governance
    • Partners
  • Science
    • Our Genome Engineering Platform
    • TALEN® Technology
    • In-House Manufacturing
  • Pipeline
    • Product Candidates
  • Investors
    • IR Overview
    • News
      • Press releases
      • Events and Webcasts
    • Presentations
      • Corporate presentations
      • Scientific presentations
      • Scientific publications
    • Corporate Governance
      • Board of Directors
      • Executive Committee
      • External Auditors
      • Governance Documents
      • General meetings
    • Financial Information
      • SEC filings
      • Financial statements
      • Voting Rights & Share Capital
      • Stock information
    • Shareholders Services
      • IR Inquiries
      • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
  • Contact us
FR
LinkedinX

Voting Rights & Share Capital

All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
19
Dec 2022
08:33 E.S.T.

Monthly information on share capital and company voting rights – November 2022

Download the PDF file
9
Nov 2022
08:33 E.S.T.

Monthly information on share capital and company voting rights – October 2022

Download the PDF file
11
Oct 2022
08:04 E.S.T.

Monthly information on share capital and company voting rights – September 2022

Download the PDF file
20
Sep 2022
07:58 E.S.T.

Monthly information on share capital and company voting rights – August 2022

Download the PDF file
23
Aug 2022
07:46 E.S.T.

Monthly information on share capital and company voting rights – July 2022

Download the PDF file
10
Jul 2022
19:32 E.S.T.

Monthly information on share capital and company voting rights – June 2022

Download the PDF file
9
Jun 2022
07:57 E.S.T.

Monthly information on share capital and company voting rights – May 2022

Download the PDF file
11
May 2022
08:22 E.S.T.

Monthly information on share capital and company voting rights – April 2022

Download the PDF file
8
Apr 2022
07:37 E.S.T.

Monthly information on share capital and company voting rights – March 2022

Download the PDF file
11
Mar 2022
08:49 E.S.T.

Monthly information on share capital and company voting rights – February 2022

Download the PDF file

Posts pagination

1 2 NEXT →

Get updates

Get the latest on gene-editing innovation, financial and business news from Cellectis with our email alert service.

Subscribe now
cellectis

Clinical-stage biotech · Dual-listed on Nasdaq (CLLS) and Euronext Growth (ALCLS).
Paris · New York · Raleigh.

  • ABOUT
    • Our mission
    • Governance
    • Partners
  • SCIENCE
    • In-House Manufacturing
    • PulseAgile Technology
    • TALEN® Technology
    • Understanding Gene Editing
  • PIPELINE
    • Product Candidates
    • BALLI-01 Trial
    • NATHALI-01 Trial
    • Patients
  • INVESTORS
    • Events
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    • Governance Documents
    • ESG report
    • Shareholders Meetings
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    • PDMR Notifications
    • IR Inquiries
    • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
© 2026 Cellectis — All rights reserved
  • Legal notice
  • Community Guidelines